


# **Work Group considerations regarding maternal RSV vaccine**

**Katherine Fleming-Dutra, MD FAAP**  
**Co-lead, Maternal/Pediatric RSV Work Group**

**ACIP General Meeting**  
**February 23, 2023**



# Policy question being considered by the work group

- Should the Pfizer RSV bivalent prefusion F vaccine be recommended for all pregnant people as a single dose given at 24–36 weeks gestation?
- This recommendation would be considered in the context of the current standard of care for prevention of RSV disease in infants at the time of ACIP vote.

# Key considerations regarding RSV bivalent prefusion F vaccine: timing of dose within pregnancy

- Dosing window in the trial was 24 through 36 weeks gestation
- Currently there are no data available on efficacy stratified by gestational age at time of administration
- Majority of infants in phase 3 trial were born  $\geq 37$  weeks gestation (94% in RSV bivalent preF arm and 95% in placebo arm)
- Most doses in the phase 3 trial were given at  $\geq 28$  weeks gestation
  - 25% doses given at  $\geq 24$  to  $< 28$  weeks
  - 30% doses given at  $\geq 28$  to  $< 32$  weeks
  - 45% doses given at  $\geq 32$  to  $< 37$  weeks
  - 0.1% doses given at  $\geq 37$  weeks

# Key considerations for RSV bivalent prefusion F vaccine: number of total lifetime doses

- All pregnant people in the trial received their first and only dose of RSV vaccine
- Currently there are no data available on
  - Efficacy of the first lifetime dose during subsequent pregnancies
  - Safety of additional doses given in subsequent pregnancies

# Proposed timeline of future ACIP presentations (tentative)

- June 2023
  - Summary of GRADE
  - Cost effectiveness analysis
  - EtR
- October 2023
  - ACIP vote (if product is licensed by this time)

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

